PROPHYLAXIS WITH EMICIZUMAB IN 8 CHILDREN WITH HEMOPHILIA A AND INHIBITORS: REAL-WORLD DATA OF A PORTUGUESE HEMOPHILIA CENTER

被引：0
|
作者：
Catarino, C. [1 ]
Campanico, S. [1 ]
Rodrigues, F. [1 ]
Pereira, A. [1 ]
机构：
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal
来源：
HAEMOPHILIA | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P085
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] PROPHYLAXIS WITH DAMOCTOCOG ALFA PEGOL: REAL WORLD USAGE AND EFFECTIVENESS IN PATIENTS WITH HEMOPHILIA A OF A PORTUGUESE HEMOPHILIA REFERENCE CENTRE
    Campanico, S.
    Catarino, C.
    Rodrigues, F.
    Pereira, A.
    Moura, L.
    Baptista, A.
    Lucas, J.
    [J]. HAEMOPHILIA, 2022, 28 : 82 - 82
  • [32] REAL WORLD DATA ON BLEEDING PATTERN IN A COHORT OF HEMOPHILIA A PATIENTS TREATED WITH EMICIZUMAB
    Levy-Mendelovich, S.
    Brutman-Barazani, T.
    Budnik, I.
    Avishai, E.
    Barg, A. A.
    Levy, T.
    Misgav, M.
    Livnat, T.
    Kenet, G.
    [J]. HAEMOPHILIA, 2022, 28 : 83 - 84
  • [33] EMICIZUMAB IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS - EXPERIENCE OF A PORTUGUESE CENTRE
    Pestana, J. S. G.
    Peixoto, C.
    Camara, C.
    Correia, C. J.
    Felix, J.
    Pires, F.
    Pereira, A.
    Rodrigues, F.
    Afonso, P.
    Rocha, E.
    Catarino, C.
    [J]. HAEMOPHILIA, 2023, 29 : 107 - 107
  • [34] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [35] IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA
    Moreno, N. A.
    Munoz-Bedoya, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [36] A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    Young, Guy
    Liesner, Ri
    Chang, Tiffany
    Sidonio, Robert, Jr.
    Oldenburg, Johannes
    Jimenez-Yuste, Victor
    Mahlangu, Johnny
    Kruse-Jarres, Rebecca
    Wang, Michael
    Uguen, Marianne
    Doral, Michelle Y.
    Wright, Lilyan Y.
    Schmitt, Christophe
    Levy, Gallia G.
    Shima, Midori
    Mancuso, Maria Elisa
    [J]. BLOOD, 2019, 134 (24) : 2127 - 2138
  • [37] Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors
    Cafuir, Lorraine
    Estrin, Adina
    Chen, Er
    Hinds, David
    Prince, Patricia
    Thorburn, Jennifer
    Mead, Henry
    Kempton, Christine L.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 984 - 992
  • [38] Real-world persistence with and adherence to Emicizumab Prophylaxis in People with Hemophilia A- Results from two secondary claims database analyses
    Khairnar, Rahul
    Meyer, Craig
    Schuldt, Robert
    Yang, Baiyu
    Tzeng, Eunice
    Lee, Lucy
    Mahajerin, Arash
    [J]. HAEMOPHILIA, 2022, 28 : 70 - 70
  • [39] Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
    Barg, Assaf A.
    Avishai, Einat
    Budnik, Ivan
    Levy-Mendelovich, Sarina
    Barazani, Tami B.
    Kenet, Gili
    Livnat, Tami
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (11)
  • [40] Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
    Giuffrida, Gaetano
    Nicolosi, Daniela
    Condorelli, Annalisa
    Markovic, Uros
    Di Raimondo, Francesco
    [J]. BLOOD, 2021, 138
12345